Table of Contents
Chapter 1 Overview of Spine Biologics
    1.1 Definition of Spine Biologics in This Report
    1.2 Commercial Types of Spine Biologics
        1.2.1 Bone Graft 
        1.2.2 Bone Graft Substitute 
        1.2.3 Platelet Rich Plasma (PRP) 
        1.2.4 BMAC (Bone Marrow Aspirate Concentrate) 
    1.3 Downstream Application of Spine Biologics
        1.3.1 Anterior Cervical Discectomy and Fusion 
        1.3.2 Posterior Lumbar Interbody Fusion 
        1.3.3 Other
    1.4 Development History of Spine Biologics
    1.5 Market Status and Trend of Spine Biologics 2013-2023
        1.5.1 Global Spine Biologics Market Status and Trend 2013-2023
        1.5.2 Regional Spine Biologics Market Status and Trend 2013-2023
Chapter 2 Global Market Status and Forecast by Regions
    2.1 Market Development of Spine Biologics 2013-2017
    2.2 Sales Market of Spine Biologics by Regions
        2.2.1 Sales Volume of Spine Biologics by Regions
        2.2.2 Sales Value of Spine Biologics by Regions
    2.3 Production Market of Spine Biologics by Regions
    2.4 Global Market Forecast of Spine Biologics 2018-2023
        2.4.1 Global Market Forecast of Spine Biologics 2018-2023
        2.4.2 Market Forecast of Spine Biologics by Regions 2018-2023
Chapter 3 Global Market Status and Forecast by Types
    3.1 Sales Volume of Spine Biologics by Types
    3.2 Sales Value of Spine Biologics by Types
    3.3 Market Forecast of Spine Biologics by Types
Chapter 4 Global Market Status and Forecast by Downstream Industry
    4.1 Global Sales Volume of Spine Biologics by Downstream Industry
    4.2 Global Market Forecast of Spine Biologics by Downstream Industry
Chapter 5 North America Market Status by Countries, Type, Manufacturers and Downstream Industry
    5.1 North America Spine Biologics Market Status by Countries
        5.1.1 North America Spine Biologics Sales by Countries (2013-2017)
        5.1.2 North America Spine Biologics Revenue by Countries (2013-2017)
        5.1.3 United States Spine Biologics Market Status (2013-2017)
        5.1.4 Canada Spine Biologics Market Status (2013-2017)
        5.1.5 Mexico Spine Biologics Market Status (2013-2017)
    5.2 North America Spine Biologics Market Status by Manufacturers
    5.3 North America Spine Biologics Market Status by Type (2013-2017)
        5.3.1 North America Spine Biologics Sales by Type (2013-2017)
        5.3.2 North America Spine Biologics Revenue by Type (2013-2017)
    5.4 North America Spine Biologics Market Status by Downstream Industry (2013-2017)
Chapter 6 Europe Market Status by Countries, Type, Manufacturers and Downstream Industry
    6.1 Europe Spine Biologics Market Status by Countries
        6.1.1 Europe Spine Biologics Sales by Countries (2013-2017)
        6.1.2 Europe Spine Biologics Revenue by Countries (2013-2017)
        6.1.3 Germany Spine Biologics Market Status (2013-2017)
        6.1.4 UK Spine Biologics Market Status (2013-2017)
        6.1.5 France Spine Biologics Market Status (2013-2017)
        6.1.6 Italy Spine Biologics Market Status (2013-2017)
        6.1.7 Russia Spine Biologics Market Status (2013-2017)
        6.1.8 Spain Spine Biologics Market Status (2013-2017)
        6.1.9 Benelux Spine Biologics Market Status (2013-2017)
    6.2 Europe Spine Biologics Market Status by Manufacturers
    6.3 Europe Spine Biologics Market Status by Type (2013-2017)
        6.3.1 Europe Spine Biologics Sales by Type (2013-2017)
        6.3.2 Europe Spine Biologics Revenue by Type (2013-2017)
    6.4 Europe Spine Biologics Market Status by Downstream Industry (2013-2017)
Chapter 7 Asia Pacific Market Status by Countries, Type, Manufacturers and Downstream Industry
    7.1 Asia Pacific Spine Biologics Market Status by Countries
        7.1.1 Asia Pacific Spine Biologics Sales by Countries (2013-2017)
        7.1.2 Asia Pacific Spine Biologics Revenue by Countries (2013-2017)
        7.1.3 China Spine Biologics Market Status (2013-2017)
        7.1.4 Japan Spine Biologics Market Status (2013-2017)
        7.1.5 India Spine Biologics Market Status (2013-2017)
        7.1.6 Southeast Asia Spine Biologics Market Status (2013-2017)
        7.1.7 Australia Spine Biologics Market Status (2013-2017)
    7.2 Asia Pacific Spine Biologics Market Status by Manufacturers
    7.3 Asia Pacific Spine Biologics Market Status by Type (2013-2017)
        7.3.1 Asia Pacific Spine Biologics Sales by Type (2013-2017)
        7.3.2 Asia Pacific Spine Biologics Revenue by Type (2013-2017)
    7.4 Asia Pacific Spine Biologics Market Status by Downstream Industry (2013-2017)
Chapter 8 Latin America Market Status by Countries, Type, Manufacturers and Downstream Industry
    8.1 Latin America Spine Biologics Market Status by Countries
        8.1.1 Latin America Spine Biologics Sales by Countries (2013-2017)
        8.1.2 Latin America Spine Biologics Revenue by Countries (2013-2017)
        8.1.3 Brazil Spine Biologics Market Status (2013-2017)
        8.1.4 Argentina Spine Biologics Market Status (2013-2017)
        8.1.5 Colombia Spine Biologics Market Status (2013-2017)
    8.2 Latin America Spine Biologics Market Status by Manufacturers
    8.3 Latin America Spine Biologics Market Status by Type (2013-2017)
        8.3.1 Latin America Spine Biologics Sales by Type (2013-2017)
        8.3.2 Latin America Spine Biologics Revenue by Type (2013-2017)
    8.4 Latin America Spine Biologics Market Status by Downstream Industry (2013-2017)
Chapter 9 Middle East and Africa Market Status by Countries, Type, Manufacturers and Downstream Industry
    9.1 Middle East and Africa Spine Biologics Market Status by Countries
        9.1.1 Middle East and Africa Spine Biologics Sales by Countries (2013-2017)
        9.1.2 Middle East and Africa Spine Biologics Revenue by Countries (2013-2017)
        9.1.3 Middle East Spine Biologics Market Status (2013-2017)
        9.1.4 Africa Spine Biologics Market Status (2013-2017)
    9.2 Middle East and Africa Spine Biologics Market Status by Manufacturers
    9.3 Middle East and Africa Spine Biologics Market Status by Type (2013-2017)
        9.3.1 Middle East and Africa Spine Biologics Sales by Type (2013-2017)
        9.3.2 Middle East and Africa Spine Biologics Revenue by Type (2013-2017)
    9.4 Middle East and Africa Spine Biologics Market Status by Downstream Industry (2013-2017)
Chapter 10 Market Driving Factor Analysis of Spine Biologics
    10.1 Global Economy Situation and Trend Overview
    10.2 Spine Biologics Downstream Industry Situation and Trend Overview
Chapter 11 Spine Biologics Market Competition Status by Major Manufacturers
    11.1 Production Volume of Spine Biologics by Major Manufacturers
    11.2 Production Value of Spine Biologics by Major Manufacturers
    11.3 Basic Information of Spine Biologics by Major Manufacturers
        11.3.1 Headquarters Location and Established Time of Spine Biologics Major Manufacturer
        11.3.2 Employees and Revenue Level of Spine Biologics Major Manufacturer
    11.4 Market Competition News and Trend
        11.4.1 Merger, Consolidation or Acquisition News
        11.4.2 Investment or Disinvestment News
        11.4.3 New Product Development and Launch
Chapter 12 Spine Biologics Major Manufacturers Introduction and Market Data
    12.1 Medtronic 
        12.1.1 Company profile
        12.1.2 Representative Spine Biologics Product
        12.1.3 Spine Biologics Sales, Revenue, Price and Gross Margin of Medtronic 
    12.2 Depuy Synthes 
        12.2.1 Company profile
        12.2.2 Representative Spine Biologics Product
        12.2.3 Spine Biologics Sales, Revenue, Price and Gross Margin of Depuy Synthes 
    12.3 Stryker Corporation 
        12.3.1 Company profile
        12.3.2 Representative Spine Biologics Product
        12.3.3 Spine Biologics Sales, Revenue, Price and Gross Margin of Stryker Corporation 
    12.4 Nuvasive 
        12.4.1 Company profile
        12.4.2 Representative Spine Biologics Product
        12.4.3 Spine Biologics Sales, Revenue, Price and Gross Margin of Nuvasive 
    12.5 Zimmer Biomet 
        12.5.1 Company profile
        12.5.2 Representative Spine Biologics Product
        12.5.3 Spine Biologics Sales, Revenue, Price and Gross Margin of Zimmer Biomet 
    12.6 Orthofix International 
        12.6.1 Company profile
        12.6.2 Representative Spine Biologics Product
        12.6.3 Spine Biologics Sales, Revenue, Price and Gross Margin of Orthofix International 
    12.7 Globus Medical 
        12.7.1 Company profile
        12.7.2 Representative Spine Biologics Product
        12.7.3 Spine Biologics Sales, Revenue, Price and Gross Margin of Globus Medical 
    12.8 alphatec spine 
        12.8.1 Company profile
        12.8.2 Representative Spine Biologics Product
        12.8.3 Spine Biologics Sales, Revenue, Price and Gross Margin of alphatec spine 
    12.9 K2M 
        12.9.1 Company profile
        12.9.2 Representative Spine Biologics Product
        12.9.3 Spine Biologics Sales, Revenue, Price and Gross Margin of K2M 
    12.10 Exactech 
        12.10.1 Company profile
        12.10.2 Representative Spine Biologics Product
        12.10.3 Spine Biologics Sales, Revenue, Price and Gross Margin of Exactech 
    12.11 Wright Medical Technology 
        12.11.1 Company profile
        12.11.2 Representative Spine Biologics Product
        12.11.3 Spine Biologics Sales, Revenue, Price and Gross Margin of Wright Medical Technology 
    12.12 X-Spine 
        12.12.1 Company profile
        12.12.2 Representative Spine Biologics Product
        12.12.3 Spine Biologics Sales, Revenue, Price and Gross Margin of X-Spine 
    12.13 Nutech 
        12.13.1 Company profile
        12.13.2 Representative Spine Biologics Product
        12.13.3 Spine Biologics Sales, Revenue, Price and Gross Margin of Nutech 
    12.14 Arthrex
        12.14.1 Company profile
        12.14.2 Representative Spine Biologics Product
        12.14.3 Spine Biologics Sales, Revenue, Price and Gross Margin of Arthrex
Chapter 13 Upstream and Downstream Market Analysis of Spine Biologics
    13.1 Industry Chain of Spine Biologics
    13.2 Upstream Market and Representative Companies Analysis
    13.3 Downstream Market and Representative Companies Analysis
Chapter 14 Cost and Gross Margin Analysis of Spine Biologics
    14.1 Cost Structure Analysis of Spine Biologics
    14.2 Raw Materials Cost Analysis of Spine Biologics
    14.3 Labor Cost Analysis of Spine Biologics
    14.4 Manufacturing Expenses Analysis of Spine Biologics
Chapter 15 Report Conclusion
Chapter 16 Research Methodology and Reference
    16.1 Methodology/Research Approach
        16.1.1 Research Programs/Design
        16.1.2 Market Size Estimation
        16.1.3 Market Breakdown and Data Triangulation
    16.2 Data Source
        16.2.1 Secondary Sources
        16.2.2 Primary Sources
    16.3 Reference

Companies Included in Reports: